(PUB) Investing 2015
6
Data through December 31, 2014 PRIMECAP Odyssey Stock
Ticker
Status Yield Total Assets
Mstar Category
POSKX Open
1.3% $3,802 mil
Large Blend
Morningstar Analyst Rating 12-19-14
Investment Style Equity Stock %
Historical Profile Return Risk Rating Above Avg Below Avg Above Avg
93% 95% 88% 87% 92% 90% 89% 90% 90%
Œ
Manager Change Partial Manager Change
14.0 18.0 22.0
Morningstar Pillars Process Performance
Growth of $10,000
Positive Positive Positive Positive Positive
∞ ∞ ∞ ∞ ∞
Investment Values of Fund Investment Values of S&P 500
10.0
People Parent Price
6.0
NAV Total Return % +/-S&P 500 +/-Russ 1000 Income Return % Capital Return % Capital Gains $ Expense Ratio % Income Ratio % Turnover Rate % Net Assets $mil Total Rtn % Rank Cat Income $ Performance Quartile (within Category) History
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 12-14
Morningstar Analyst Rating Morningstar evaluates mutual funds based on five key pillars, which its analysts believe lead to funds that are more likely to outperform over the long term on a risk-adjusted basis. Analyst Rating Spectrum Œ „ ´ˇ ¨
10.92 . . 11.05 . . 6.14 . . 4.78 . . 0.04 . . 11.01 . . 18 . . 0.00 . . 0.00 . . 1.25 . . -0.11 . . 12 . .
12.12 14.01 -1.78 -1.45
13.70
14.08
9.33
12.77 11.82 -3.24 -4.28
14.17 2.07 -0.04 0.57 1.26 0.81
14.28 13.62 -2.38 -2.80
15.98 34.39
23.66 15.04
-33.27 4.18
37.86 11.40
-1.31 -1.59 0.51
3.73 4.33 0.46
2.00 1.28 1.51
1.35 1.80 1.47
9.43 0.97
0.33
0.84
1.73
13.68
-33.73 3.67
36.89
10.98
11.89
32.88
13.57
7
90
6
35
81
13
70
25
8
Pillar Spectrum Positive ∞
0.00 0.00 0.99 0.41
0.04 0.08 0.81 0.59
0.07 0.12 0.79 0.51
0.06 0.00 0.80 0.96
0.09 0.00 0.71 1.37
0.11 0.00 0.66 1.25
0.18 0.00 0.66 1.57
0.25 0.00 0.63 1.65
0.31 0.35 0.62 1.34
§ Negative
¶ Neutral
Performance 12-31-14 1st Qtr 2nd Qtr
3rd Qtr
4th Qtr
Total
4
6
10
34
3
24
11
15
8
2010 2011 2012 2013 2014
4.70 -11.07 2.07 5.15 1.28 -13.85 11.25 13.62 8.68 -2.77 4.37 3.02 34.39 12.20 4.02 6.11 8.52 15.04 3.83 3.55 1.98 . . 9.34 9.84
10
34
98
206
200
266
679
1,057
1,612
2,272
3,802
.
Portfolio Analysis 09-30-14 Share change since 06-14 Total Stocks:115 Sector
Rating and Risk Time Load-Adj
PE Tot Ret% % Assets
Morningstar
Morningstar Risk vs Cat
Morningstar Risk-Adj Rating
Period Return % Rtn vs Cat
Dreyfus Treasury Pr Cash
. . . Hlth care 27.6 39.12 3.97 Hlth care 21.5 -0.66 3.60 Hlth care 25.1 41.77 3.57 Finan Svs 32.3 17.04 3.15 Hlth care 17.3 17.19 3.09 Technology 18.2 27.24 2.66 Technology 23.2 24.58 2.48 10.10 Cnsmr Cyc 25.1 15.33 2.23 Cnsmr Cyc 26.6 43.75 2.13 Technology 18.9 27.31 2.02 Finan Svs 29.3 17.93 2.00 Finan Svs 13.4 23.72 1.80 Hlth care 24.9 27.89 1.78 Cnsmr Cyc 22.2 26.87 1.62 Technology 15.3 45.66 1.59 Hlth care 22.5 18.66 1.58 Hlth care 32.1 21.42 1.55 Industrl 25.6 125.80 2.36 Energy . -57.22 1.87
1 Yr 3 Yr 5 Yr
15.04 20.66 14.93
Trailing
Total
+/-
+/- Russ %Rank Growth of
Eli Lilly and Co
Return% S&P 500 4.93 0.00 7.00 0.88 15.04 1.35 20.66 0.25 14.93 -0.52 9.30 1.63
1000 0.05 1.43 1.80 0.04 -0.71 1.34
Cat
$10,000
+Avg +Avg High
Low -Avg -Avg
Roche Holding AG Dividen
3 Mo 6 Mo 1 Yr
32 10,493 10 10,700 8 11,504 25 17,567 29 20,052
Amgen Inc
10 Yr Incept
9.30
Charles Schwab Corp Johnson & Johnson Texas Instruments Inc Southwest Airlines Co Microsoft Corp Cisco Systems Inc CME Group Inc Class A Transocean Ltd Wells Fargo & Co Medtronic Inc Ross Stores Inc Hewlett-Packard Co Novartis AG ADR Biogen Idec Inc Carnival Corp L Brands Inc
10.09
3 Yr Avg 5 Yr Avg 10 Yr Avg 15 Yr Avg
Other Measures
Standard Index
Best Fit Index
S&P 500
M* U.S. Core TR
3 24,333 . . . . . Tax Analysis Tax-Adj Rtn% %Rank Cat Tax-Cost Rat %Rank Cat
Alpha
3.0
2.2
Beta
0.85
0.83
R-Squared
89
92
3 Yr (estimated) 5 Yr (estimated) 10 Yr (estimated)
19.83 14.35
15 19
0.69 0.50 0.36
30 27 10
Standard Deviation
8.18
Mean
20.66
8.90
1
Sharpe Ratio
2.35
Potential Capital Gain Exposure: 26% of assets
Morningstar’s Take by David Kathman, CFA 12-19-14 A new comanager won’t mean significant changes for Primecap Odyssey Growth. On Dec. 10, 2014, James Marchetti was officially named comanager of this fund and Primecap Odyssey Aggressive Growth POAGX and Odyssey Growth POGRX, effective Nov. 1, and he’s expected to be named comanager of the same team’s Vanguard funds, including Vanguard Primecap VPMCX, in the near future. This move doesn’t represent any change in how the funds are managed, as Marchetti has had portfolio responsibilities since the beginning of 2014 and has been a key analyst for several years, managing a sleeve of health-care stocks. This promotion comes at the end of a strong year in which this fund ranked in the large-blend category’s top 1% for the year to date as of mid-December. This is the third year of top-quartile returns out of the past four for this fund, which has also ranked in the category’s top 5% in the decade since its inception. These great results are hardly a surprise, given that the Primecap team has compiled one of the fund industry’s
most impressive track records over the past 30 years with Vanguard Primecap. They use the same patient contrarian growth strategy here, looking for stocks with good long-term growth potential but temporarily depressed valuations. Of the three Primecap Odyssey funds, this is the least aggressive, with a portfolio dominated by mega-caps, and the most similar to Vanguard Primecap. Like its siblings, this fund is especially heavy in health-care and technology stocks, which make up more than half of the portfolio. Many of the fund’s pharmaceutical and biotech stocks, in particular, struggled a few years ago, but the managers were patient, and most of those stocks have posted nice gains recently, contributing to the fund’s better performance. Since Primecap Odyssey Aggressive Growth closed to new investors in early 2014, this fund and Primecap Odyssey Growth are the only two of the team’s six funds that remain open. Both are excellent core funds with great track records and very low expenses; this fund is better suited for more-conservative investors.
Current Investment Style
Sector Weightings
% of Stocks
Rel S&P 500 High
3 Year Low
Market Cap % Giant 43.6 Large 36.3 Mid 14.6 Small 4.1 Micro 1.3 Avg $mil: 44,084
Value Blnd Growth
Large Mid Small
Cyclical 27.43 BasicMat 3.40 CnsmrCyc11.10 FinanSvs 12.93 Real Est 0.00 Sensitive 42.94 CommSrvs 0.24 Energy 4.51 Industrl 12.16 Technlgy 26.03 Defensive29.63 CnsmrDef 1.07 Hlthcare 28.03 Utilities 0.53
. .
h r t y u j i o p a k s d f
5 3
. 11 9 . 15 10 . . .
. . .
1 0 7 5
Value Measures Price/Earnings Price/Book Price/Sales Price/Cash Flow Dividend Yield % Long-Term Erngs Book Value Sales Cash Flow Historical Erngs Growth Measures
Rel Category
18.49 2.57 1.95 10.93 2.17 10.98 5.68 2.49 1.71 6.41
1.29 1.26 1.55 1.54 1.00 1.06 1.07 0.86 0.25 0.36
. 14 11 . 26 19
. .
4 1
. 32 28
% Rel Category
2 1
.
Composition - Net
Cash 10.1 Stocks 89.9 Bonds 0.0 Other 0.0 Foreign 14.4
Address:
PRIMECAP Odyssey Funds Pasadena, CA 91101 800-729-2307 www.odysseyfunds.com
Minimum Purchase: Min Auto Inv Plan:
$2000 $2000
Add: $100 IRA: $1000
Add: $100
Profitability
% Rel Category
Sales Fees:
No-load
Return on Equity Return on Assets Net Margin
20.42 8.41 15.46
1.06 1.09 1.22
Web Address: Inception: Advisor: Subadvisor: NTF Plans:
Management Fee:
0.60% mx./0.55% mn. Mgt:0.55% Dist: .
(% of Stock)
11-01-04
Actual Fees:
PRIMECAP Management Company
Expense Projections: Income Distribution:
3Yr:$205 Annually
5Yr:$357 10Yr:$798
None
N/A
Mutual Funds ß ®
© 2015Morningstar, Inc.All rights reserved.The informationherein is not represented orwarranted tobeaccurate, correct, completeor timely. Pastperformance is no guarantee of future results.Access updated reportsat Toorder reprints, call312-696-6100. mfb.morningstar.com.
EQ
Made with FlippingBook